Brokers Offer Predictions for Gilead Sciences Q4 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings per share estimates for shares of Gilead Sciences in a research note issued on Wednesday, February 12th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will post earnings of $1.72 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.35 per share.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%.

GILD has been the subject of several other reports. Wells Fargo & Company lifted their price objective on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday. Wolfe Research assumed coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $101.33.

Gilead Sciences Stock Performance

GILD stock opened at $104.08 on Friday. The stock has a 50-day moving average price of $93.87 and a 200-day moving average price of $87.55. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $106.69. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $129.71 billion, a PE ratio of 1,156.44, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.04%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 710,500 shares of company stock worth $67,684,956. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of large investors have recently made changes to their positions in GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth $25,000. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $29,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.